TY - JOUR
T1 - The VEGF/Rho GTPase signalling pathway
T2 - a promising target for anti-angiogenic/anti-invasion therapy
AU - van der Meel, Roy
AU - Symons, Marc H.
AU - Kudernatsch, Robert
AU - Kok, Robbert J.
AU - Schiffelers, Raymond M.
AU - Storm, Gert
AU - Gallagher, William M.
AU - Byrne, Annette T.
N1 - Copyright © 2011. Published by Elsevier Ltd.
PY - 2011/3
Y1 - 2011/3
N2 - It has become increasingly apparent that current antiangiogenic therapy elicits modest effects in clinical settings. In addition, it remains challenging to treat cancer metastasis through antiangiogenic regimes. Rho GTPases are essential for vascular endothelial growth factor (VEGF)-mediated angiogenesis and are involved in tumour cell invasion. This review discusses novel therapeutic strategies that interfere with Rho GTPase signalling and further explores this network as a target for anticancer therapy through interference with tumour angiogenesis and invasion. Recent findings describe the development of innovative Rho GTPase inhibitors. Positive clinical effects of Rho GTPase targeting in combination with conventional anticancer therapy is of increasing interest.
AB - It has become increasingly apparent that current antiangiogenic therapy elicits modest effects in clinical settings. In addition, it remains challenging to treat cancer metastasis through antiangiogenic regimes. Rho GTPases are essential for vascular endothelial growth factor (VEGF)-mediated angiogenesis and are involved in tumour cell invasion. This review discusses novel therapeutic strategies that interfere with Rho GTPase signalling and further explores this network as a target for anticancer therapy through interference with tumour angiogenesis and invasion. Recent findings describe the development of innovative Rho GTPase inhibitors. Positive clinical effects of Rho GTPase targeting in combination with conventional anticancer therapy is of increasing interest.
KW - Angiogenesis Inhibitors/pharmacology
KW - Animals
KW - Antineoplastic Agents/pharmacology
KW - Drug Delivery Systems
KW - Humans
KW - Neoplasm Invasiveness
KW - Neoplasm Metastasis
KW - Neoplasms/blood supply
KW - Neovascularization, Pathologic/drug therapy
KW - Signal Transduction/drug effects
KW - Vascular Endothelial Growth Factor A/metabolism
KW - rho GTP-Binding Proteins/antagonists & inhibitors
U2 - 10.1016/j.drudis.2011.01.005
DO - 10.1016/j.drudis.2011.01.005
M3 - Review article
C2 - 21262381
SN - 1359-6446
VL - 16
SP - 219
EP - 228
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 5-6
ER -